Abstract
Erectile dysfunction (ED) is one of the most challenging complications associated with radical prostatectomy (RP) for clinically localized prostate cancer. Currently, a broad spectrum of therapeutic options are available to improve sexual health after surgical treatment. Several basic science reports highlighted a potential role for phosphodiesterase type 5 inhibitors in the prevention of endothelial damage related to ischemia reperfusion and/or denervation following surgery. Recent studies have shown that pharmacological prophylaxis soon after RP can significantly improve the rate at which erectile function is recovered after surgery. Use of on-demand treatments for ED in patients who have undergone RP has been shown to be highly effective. In this context, pharmacological prophylaxis potentially may have a significantly expanded role in future strategies aimed at preserving postoperative erectile function. We analyzed the factors affecting erectile function after RP and evaluated the evidence suggesting the role of pharmacological prophylaxis and treatment of ED after surgery.
Keywords: Erectile dysfunction, radical prostatectomy, phosphodiesterase-5 inhibitors
Current Pharmaceutical Design
Title: Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Volume: 15 Issue: 30
Author(s): F. Deho, A. Gallina, A. Salonia, A. Briganti, N. Suardi, G. Zanni, G. Guazzoni, P. Rigatti and F. Montorsi
Affiliation:
Keywords: Erectile dysfunction, radical prostatectomy, phosphodiesterase-5 inhibitors
Abstract: Erectile dysfunction (ED) is one of the most challenging complications associated with radical prostatectomy (RP) for clinically localized prostate cancer. Currently, a broad spectrum of therapeutic options are available to improve sexual health after surgical treatment. Several basic science reports highlighted a potential role for phosphodiesterase type 5 inhibitors in the prevention of endothelial damage related to ischemia reperfusion and/or denervation following surgery. Recent studies have shown that pharmacological prophylaxis soon after RP can significantly improve the rate at which erectile function is recovered after surgery. Use of on-demand treatments for ED in patients who have undergone RP has been shown to be highly effective. In this context, pharmacological prophylaxis potentially may have a significantly expanded role in future strategies aimed at preserving postoperative erectile function. We analyzed the factors affecting erectile function after RP and evaluated the evidence suggesting the role of pharmacological prophylaxis and treatment of ED after surgery.
Export Options
About this article
Cite this article as:
Deho F., Gallina A., Salonia A., Briganti A., Suardi N., Zanni G., Guazzoni G., Rigatti P. and Montorsi F., Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206999
DOI https://dx.doi.org/10.2174/138161209789206999 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Isolation, Purification and Characterization of a Novel Steroidal Saponin Cholestanol Glucoside from Lasiodiplodia theobromae that Induces Apoptosis in A549 Cells
Anti-Cancer Agents in Medicinal Chemistry Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology Identification of Tumor Targeting Agents by Phage Display
Medicinal Chemistry Reviews - Online (Discontinued) Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Graphical Abstracts
Letters in Drug Design & Discovery Protein Metabolism and Signal Pathway Regulation in Rumen and Mammary Gland
Current Protein & Peptide Science The Tumor Stroma as Mediator of Drug Resistance - A Potential Target to Improve Cancer Therapy?
Current Pharmaceutical Biotechnology The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Design, Synthesis and Pharmacological Evalution of 1,3,4-Oxadiazole Derivatives as Collapsin Response Mediator Protein 1 (CRMP 1) Inhibitors
Current Drug Discovery Technologies Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science Pulmonary Neuroendocrine Cell System in Health and Disease
Current Respiratory Medicine Reviews Zinc Tetrafluoroborate Catalyzed Synthesis, Molecular Docking and Cytotoxicity of Pyrrolidinyl Aminophosphonates
Letters in Drug Design & Discovery Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science